Patients appeal NIH's rejection to use 'march-in' rights on Astellas' prostate cancer drug Xtandi
NIH declined to use “march-in” rights to lower the price of Astellas’ and Pfizer’s prostate cancer drug Xtandi earlier this week, and now the patients behind the petition are asking the federal agency to reconsider.
The appeal, dated Thursday and shared with Endpoints News, was addressed to HHS secretary Xavier Becerra and asked that HHS reconsider the patients’ appeal directly — and not assign NIH to reexamine its own decision.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.